Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases

Gastroenterology

Volumn 154, Issue 5, 2018, Pages 1320-1333.e10

  Šimurina, Mirna ^a   de Haan, Noortje ^b   Vučković, Frano ^c   Kennedy, Nicholas A ^d   Štambuk, Jerko ^c   Falck, David ^b   Trbojević Akmačić, Irena ^c   Clerc, Florent ^b   Razdorov, Genadij ^c   Khon, Anna ^e   Latiano, Anna ^f   D'Incà, Renata ^g   Danese, Silvio ^h   Targan, Stephan ⁱ   Landers, Carol ⁱ   Dubinsky, Marla ⁱ   Campbell, Harry ^l   Zoldoš, Vlatka ^l   Permberton, Iain K ^l   Kolarich, Daniel ^l   Fernandes, Daryl L ^l   Theorodorou, Evropi ^l   Merrick, Victoria ^l   Spencer, Daniel I ^l   Gardner, Richard A ^l   Doran, Ray ^l   Shubhakar, Archana ^l   Boyapati, Ray ^l   Rudan, Igor ^l   Lionetti, Paolo ^l   Krištić, Jasminka ^l   Novokmet, Mislav ^l   Pučić Baković, Maja ^l   Gornik, Olga ^l   Andriulli, Angelo ^l   Cantoro, Laura ^l   Sturniolo, Giancarlo ^l   Fiorino, Gionata ^l   Manetti, Natalia ^l   Arnott, Ian D ^l   Noble, Colin L ^l   Lees, Charlie W ^l   Shand, Alan G ^l   Ho, Gwo Tzer ^l   Dunlop, Malcolm G ^l   Murphy, Lee ^l   Gibson, Jude ^l   Evenden, Louise ^l   Wrobel, Nicola ^l   Gilchrist, Tamara ^l   Fawkes, Angie ^l   Kammeijer, Guinevere S M ^l   Vojta, Aleksandar ^l   Samaržija, Ivana ^l   Markulin, Dora ^l   Klasić, Marija ^l   Dobrinić, Paula ^l   Aulchenko, Yurii ^l   van den Heuve, Tim ^l   Jonkers, Daisy ^l   Pierik, Marieke ^l   McGovern, Dermot P B ⁱ   Annese, Vito ^j,k   Wuhrer, Manfred ^b   Lauc, Gordan ^a,c   more..

^a UNIVERSITY OF ZAGREB   (Croatia)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^d UNIVERSITY OF EXETER   (United Kingdom)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h HUMANITAS UNIVERSITY   (Italy)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

^k University of Pretoria   (United Arab Emirates)

^l NONE

more..

Author keywords

Biomarker; Glycans; Glycopeptides; IBD

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; BIOLOGICAL MARKER; GLYCOPEPTIDE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G23; IMMUNOGLOBULIN G4; MESALAZINE; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FUCOSYLATION; HUMAN; ITALY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SIALYLATION; STEROID THERAPY; TANDEM MASS SPECTROMETRY; ULCERATIVE COLITIS; UNITED STATES; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; GLYCOSYLATION; IMMUNOLOGY; META ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PROGNOSIS; PROTEIN PROCESSING; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AREA UNDER CURVE; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 85044617800     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.01.002     Document Type: Article

References (105)

1. Burisch, J., Pedersen, N., Čuković-Čavka, S., et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 63 (2014), 588–597.
2. Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.e42 quiz e30.
3. Burisch, J., Jess, T., Martinato, M., et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 7 (2013), 322–337.
4. Burisch, J., Munkholm, P., Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol 29 (2013), 357–362.
5. Crohn's and Colitis Foundation of America. The facts about inflammatory bowel diseases. Available at: http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf. Accessed February 17, 2017.
6. Satsangi, J., Silverberg, M.S., Vermeire, S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006), 749–753.
7. Xavier, R.J., Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427–434.
8. Jostins, L., Ripke, S., Weersma, R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
9. Walt, D., Aoki-Kinoshita, K.F., Bendiak, B., et al. Transforming Glycoscience: A Roadmap for the Future. 2012, National Academies Press, Washington, DC.
10. Krištić J., Lauc, G., Ubiquitous Importance of protein glycosylation. Methods Mol Biol 1503 (2017), 1–12.
11. Subedi, G.P., Barb, A.W., The structural role of antibody N-glycosylation in receptor interactions. Structure 23 (2015), 1573–1583.
12. Vučković F., Krištić J., Gudelj, I., et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol 67 (2015), 2978–2989.
13. Gornik, O., Lauc, G., Glycosylation of serum proteins in inflammatory diseases. Dis Markers 25 (2008), 267–278.
14. Häuselmann, I., Borsig, L., Altered tumor-cell glycosylation promotes metastasis. Front Oncol, 4, 2014, 28.
15. Vučković F., Theodoratou, E., Thaçi, K., et al. IgG glycome in colorectal cancer. Clin Cancer Res 22 (2016), 3078–3086.
16. Pinho, S.S., Reis, C.A., Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15 (2015), 540–555.
17. Dubé R., Rook, G.A., Steele, J., et al. Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut 31 (1990), 431–434.
18. Shinzaki, S., Iijima, H., Nakagawa, T., et al. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol 103 (2008), 1173–1181.
19. Dias, A.M., Dourado, J., Lago, P., et al. Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. Hum Mol Genet 23 (2014), 2416–2427.
20. Lichtenstein, G.R., McGovern, D.P.B., Using markers in IBD to predict disease and treatment outcomes: rationale and a review of current status. Am J Gastroenterol Suppl 3 (2016), 17–26.
21. Panes, J., Jairath, V., Levesque, B.G., Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 152 (2017), 362–373.e3.
22. Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol 13 (2013), 176–189.
23. Lauc, G., Pezer, M., Rudan, I., et al. Mechanisms of disease: the human N-glycome. Biochim Biophys Acta 1860 (2016), 1574–1582.
24. Trbojević Akmačić I., Ventham, N.T., Theodoratou, E., et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis, 21, 2015, 1.
25. Franke, A., McGovern, D.P.B., Barrett, J.C., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42 (2010), 1118–1125.
26. Lauc, G., Huffman, J.E., Pučić M., et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet, 9, 2013, e1003225.
27. Pezer, M., Stambuk, J., Perica, M., et al. Effects of allergic diseases and age on the composition of serum IgG glycome in children. Sci Rep, 6, 2016, 33198.
28. Arnold, J.N., Wormald, M.R., Sim, R.B., et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25 (2007), 21–50.
29. Menni, C., Keser, T., Mangino, M., et al. Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. PLoS One, 8, 2013, e82558.
30. Pučić M., Knezević A., Vidic, J., et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics, 10, 2011 M111.010090.
31. Novokmet, M., Lukić E., Vučković F., et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep, 4, 2014, 4347.
32. Krištić J., Vuckovic, F., Menni, C., et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci 69 (2013), 779–789.
33. Kaneko, Y., Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
34. Scanlan, C.N., Burton, D.R., Dwek, R.A., Making autoantibodies safe. Proc Natl Acad Sci U S A 105 (2008), 4081–4082.
35. Gasdaska, J.R., Sherwood, S., Regan, J.T., et al. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol 50 (2012), 134–141.
36. Thomann, M., Reckermann, K., Reusch, D., et al. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol 73 (2016), 69–75.
37. Thomann, M., Schlothauer, T., Dashivets, T., et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One, 10, 2015, e0134949.
38. Subedi, G.P., Barb, A.W., The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fcγ receptor. MAbs 8 (2016), 1512–1524.
39. Schwab, I., Lux, A., Nimmerjahn, F., Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice. Cell Rep 13 (2015), 610–620.
40. Washburn, N., Schwab, I., Ortiz, D., et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A 112 (2015), E1297–E1306.
41. Kao, D., Danzer, H., Collin, M., et al. A monosaccharide residue is sufficient to maintain mouse and human IgG subclass activity and directs IgG effector functions to cellular Fc receptors. Cell Rep 13 (2015), 2376–2385.
42. Bondt, A., Wuhrer, M., Kuijper, T.M., et al. Fab glycosylation of immunoglobulin G does not associate with improvement of rheumatoid arthritis during pregnancy. Arthritis Res Ther, 18, 2016, 274.
43. Selman, M.H.J., Derks, R.J.E., Bondt, A., et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics 75 (2012), 1318–1329.
44. Falck, D., Jansen, B.C., de Haan, N., et al. High-throughput analysis of IgG Fc glycopeptides by LC-MS. Methods Mol Biol 1503 (2017), 31–47.
45. Dubinsky, M.C., Kugathasan, S., Kwon, S., et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis 19 (2013), 1662–1670.
46. Cleynen, I., Boucher, G., Jostins, L., et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387 (2016), 156–167.
47. Haritunians, T., Taylor, K.D., Targan, S.R., et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 16 (2010), 1830–1840.
48. Baković M.P., Selman, M.H.J., Hoffmann, M., et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res 12 (2013), 821–831.
49. Jansen, B.C., Falck, D., de Haan, N., et al. LaCyTools: a targeted liquid chromatography-mass spectrometry data processing package for relative quantitation of glycopeptides. J Proteome Res 15 (2016), 2198–2210.
50. Balbín, M., Grubb, A., de Lange, G.G., et al. DNA sequences specific for Caucasian G3m(b) and (g) allotypes: allotyping at the genomic level. Immunogenetics 39 (1994), 187–193.
51. Selman, M.H.J., McDonnell, L.A., Palmblad, M., et al. Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem 82 (2010), 1073–1081.
52. Viechtbauer, W., Conducting meta-analyses in R with the metafor Package. J Stat Softw 36 (2010), 1–48.
53. Friedman, J., Hastie, T., Tibshirani, R., Regularization paths for generalized linear models via Coordinate Descent. J Stat Softw 33 (2010), 1–22.
54. Shinzaki, S., Iijima, H., Fujii, H., et al. Altered oligosaccharide structures reduce colitis induction in mice defective in β-1,4-galactosyltransferase. Gastroenterology 142 (2012), 1172–1182.
55. Anthony, R.M., Wermeling, F., Ravetch, J.V., Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 1253 (2012), 170–180.
56. Ercan, A., Cui, J., Chatterton, D.E.W., et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 62 (2010), 2239–2248.
57. Rombouts, Y., Ewing, E., van de Stadt, L.A., et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74 (2015), 234–241.
58. Ito, K., Furukawa, J., Yamada, K., et al. Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies. J Immunol 192 (2014), 581–588.
59. Bondt, A., Selman, M.H.J., Deelder, A.M., et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res 12 (2013), 4522–4531.
60. Kemna, M.J., Plomp, R., van Paassen, P., et al. Galactosylation and sialylation levels of IgG predict relapse in patients with PR3-ANCA associated vasculitis. EBioMedicine 17 (2017), 108–118.
61. Shakib, F., Stanworth, D.R., Human IgG subclasses in health and disease (A review) Part II. Ric Clin Lab 10 (1980), 561–580.
62. Lee, J.C., Biasci, D., Roberts, R., et al. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nat Genet 49 (2017), 262–268.
63. Dubinsky, M.C., Lin, Y.-C., Dutridge, D., et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 101 (2006), 360–367.
64. Marigorta, U.M., Denson, L.A., Hyams, J.S., et al. Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease. Nat Genet 49 (2017), 1517–1521.
65. Siegel, C.A., Horton, H., Siegel, L.S., et al. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther 43 (2016), 262–271.
66. Yoon, S.M., Haritunians, T., Chhina, S., et al. Colonic phenotypes are associated with poorer response to anti-TNF therapies in patients with IBD. Inflamm Bowel Dis 23 (2017), 1382–1393.
67. Gornik, O., Wagner, J., Pucić M., et al. Stability of N-glycan profiles in human plasma. Glycobiology 19 (2009), 1547–1553.
68. Soubières, A.A., Poullis, A., Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel diseases. Inflamm Bowel Dis 22 (2016), 2016–2022.
69. Bennike, T., Birkelund, S., Stensballe, A., et al. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol 20 (2014), 3231–3244.
70. Panaccione, R., Mechanisms of inflammatory bowel disease. Gastroenterol Hepatol (N Y) 9 (2013), 529–532.
71. Karsten, C.M., Pandey, M.K., Figge, J., et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med 18 (2012), 1401–1406.
72. Shields, R.L., Lai, J., Keck, R., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002), 26733–26740.
73. Zou, G., Ochiai, H., Huang, W., et al. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. J Am Chem Soc 133 (2011), 18975–18991.
74. Ferrara, C., Brünker, P., Suter, T., et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93 (2006), 851–861.
75. Gornik, O., Pavić T., Lauc, G., Alternative glycosylation modulates function of IgG and other proteins—implications on evolution and disease. Biochim Biophys Acta 1820 (2012), 1318–1326.
76. Cosnes, J., Gower-Rousseau, C., Seksik, P., et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140 (2011), 1785–1794.
77. D'Haens, G.R., Panaccione, R., Higgins, P.D.R., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 106 (2011), 199–212 quiz 213.
78. Mowat, C., Cole, A., Windsor, A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 60 (2011), 571–607.
79. Liu, D., Ahmet, A., Ward, L., et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol, 9, 2013, 30.
80. Fiebiger, B.M., Maamary, J., Pincetic, A., et al. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci 112 (2015), E2385–E2394.
81. Jannetto, P.J., Fitzgerald, R.L., Effective use of mass spectrometry in the clinical laboratory. Clin Chem 62 (2016), 92–98.
82. Vanderschaeghe, D., Szekrényes, A., Wenz, C., et al. High-throughput profiling of the serum n-glycome on capillary electrophoresis microfluidics systems: toward clinical implementation of GlycoHepatoTest. Anal Chem 82 (2010), 7408–7415.
83. Annese, V., Lombardi, G., Perri, F., et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease—an IG-IBD study. Am J Gastroenterol 100 (2005), 84–92.
84. Latiano, A., Palmieri, O., Valvano, R.M., et al. Contribution of IBD5 locus to clinical features of IBD patients. Am J Gastroenterol 101 (2006), 318–325.
85. Latiano, A., Palmieri, O., Valvano, M.R., et al. Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis 13 (2007), 1212–1219.
86. Latiano, A., Palmieri, O., Cucchiara, S., et al. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Am J Gastroenterol 104 (2009), 110–116.
87. Latiano, A., Palmieri, O., Corritore, G., et al. Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflamm Bowel Dis 16 (2010), 1108–1117.
88. Palmieri, O., Latiano, A., Scimeca, D., et al. IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. Inflamm Bowel Dis 17 (2011), 1832–1833.
89. Latiano, A., Palmieri, O., Latiano, T., et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. Niess J-H, ed PLoS One, 6, 2011, e22688.
90. Latiano, A., Palmieri, O., Pastorelli, L., et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One, 8, 2013, e62144.
91. Dassopoulos, T., Nguyen, G.C., Bitton, A., et al. Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm Bowel Dis 13 (2007), 975–983.
92. Cleynen, I., Boucher, G., Jostins, L., et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (London, England) 387 (2016), 156–167.
93. Dubinsky, M.C., Kugathasan, S., Kwon, S., et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis 19 (2013), 1662–1670.
94. Haritunians, T., Taylor, K.D., Targan, S.R., et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 16 (2010), 1830–1840.
95. Kaur, M., Panikkath, D., Yan, X., et al. Perianal Crohn's disease is associated with distal colonic disease, stricturing disease behavior, IBD-associated serologies and genetic variation in the JAK-STAT pathway. Inflamm Bowel Dis 22 (2016), 862–869.
96. Pučić M., Knezević A., Vidic, J., et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics, 10, 2011 M111.010090.
97. Falck, D., Jansen, B.C., de, Haan N., et al. High-throughput analysis of IgG Fc glycopeptides by LC-MS. Methods Mol Biol 1503 (2017), 31–47.
98. Selman, M.H.J., Derks, R.J.E., Bondt, A., et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics 75 (2012), 1318–1329.
99. Jansen, B.C., Falck, D., de Haan, N., et al. LaCyTools: a targeted liquid chromatography-mass spectrometry data processing package for relative quantitation of glycopeptides. J Proteome Res 15 (2016), 2198–2210.
100. Balbín, M., Grubb, A., de Lange, G.G., et al. DNA sequences specific for Caucasian G3m(b) and (g) allotypes: allotyping at the genomic level. Immunogenetics 39 (1994), 187–193.
101. Selman, M.H.J., McDonnell, L.A., Palmblad, M., et al. Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem 82 (2010), 1073–1081.
102. Arnold, J.N., Wormald, M.R., Sim, R.B., et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25 (2007), 21–50.
103. Johnson, W.E., Li, C., Rabinovic, A., Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 (2007), 118–127.
104. Viechtbauer, W., Conducting meta-analyses in R with the metafor Package. J Stat Softw 36 (2010), 1–48.
105. Friedman, J., Hastie, T., Tibshirani, R., Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33 (2010), 1–22.